Previous close | 6.80 |
Open | 6.79 |
Bid | 0.00 x 900 |
Ask | 0.00 x 800 |
Day's range | 6.57 - 6.76 |
52-week range | 5.92 - 32.04 |
Volume | |
Avg. volume | 21,827 |
Market cap | 216.582M |
Beta (5Y monthly) | 0.94 |
PE ratio (TTM) | 1.95 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
It's hard for any stock to deliver positive gains while the market is falling. Molecular Partners' (NASDAQ: MOLN) shares have skyrocketed more than 40% year to date. On Jan. 10, Molecular Partners and Novartis announced positive results from their Empathy phase 2 study of ensovibep in treating acute COVID-19 patients.
Novartis and Molecular Partners reported positive results for COVID-19 candidate ensovibep.
Regulatory and other pipeline updates from Biogen (BIIB) and AMGN are among a few key highlights from the biotech sector during the past week.